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Requirement for Metabolic Activation of
Acetylaminofluorene to Induce Multidrug
Gene Expression
Timothy W. Gant, Dieter Schrenk, Jeffrey A. Silverman, and
Snorri S. Thorgeirsson
National Cancer Institute, Bethesda, Maryland
Previously we have demonstrated that several xenobiotics can induce multidrug (mdr) gene expression in cultures of primary isolated hepatocytes.
One of the best of these xenobiotic inducers in rat hepatocytes is 2-acetylaminofluorene (2-AAF), which induces mdr expression by an enhance-
ment of mdr gene transcription. In all species studied to date, AAF is extensively and variously metabolized. In this study we have sought to deter-
mine if AAF per se or a metabolite is responsible for mediating the increase in mdr gene transcription and expression. This study demonstrates that
AAF per se is not active, but that the effect of AAF we have observed on mdrgene transcription and expression in the rat is due to the formation of
a reactive metabolite(s). Our data indicate that this reactive metabolite is probably N-acetoxy-2-aminofluorene or the sulfate ester of N-hydroxy-AAF.
The requirement for the formation of one of these metabolites may explain the differences in species response to AAF, in terms of mdr gene
expression, that we have observed. We hypothesize that the mechanism by which mdrgene transcription is increased in response to AAF involves
a covalent interaction between a reactive metabolite and an mdrgene regulatory protein. Our current work is concerned with the exploration of this
hypothesis. - Environ Health Perspect 102(Suppl 6):209-212 (1994)
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Introduction
The multidrug (mdr) resistance phenotype
occurs commonly in tumors prior to and
after exposure to chemotherapeutic agents
and can arise by several different mecha-
nisms (1-3). One mechanism by which an
mdr phenotype is developed is via overex-
pression of a membrane transport protein,
P-glycoprotein (P-gp) (4-7). This protein
operates as a plasma membrane pump to
transfer xenobiotic molecules across the
plasma membrane and out of the cell
against a concentration gradient (8-11).
Energy for this process is derived from the
hydrolysis of ATP (9,10,12). P-gps are
encoded by a family of genes consisting of
two members in humans, primates, rabbits,
and fish; generally three in rodents; four in
the dog; and five in the pig (13). The genes
generally divide into two classes: mdrl and
mdr2. The mdrl genes encode a P-gp that
confers drug resistance while the mdr2
genes code for a P-gp that does not.
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Humans and primates have a mdrl and
mdr2 gene. Rodents also have only one
mdr2gene but have two genes in the mdrl
class. These genes are variously named in
the literature, but we refer to them as
mdrla and mdrlb in accordance with the
nomenclature proposed by Hsu et al. (14).
The P-gps are part ofa much larger protein
familyknown as theABC proteins orATP-
binding cassette proteins (15-17).
Members of this family include the yeast
STE6 factor transporter to which P-gp is
closely related and the cystic fibrosis trans-
membrane conductor (18,19).
The expression levels ofP-gp are variable
in tumors both at the time ofdiagnosis and
after treatment with chemotherapeutic
agents (20). Normal expression of P-gp is
highest in the intestine, kidney (proximal
convoluted tubule), on the bile canalicular
surface of the hepatocyte, the blood brain
barrier, in the adrenal gland, and in the
uterus of a pregnant animal (mouse) (21-
25). Tumors derived from these tissues
normally have the highest pretreatment
levels of P-gp (20,26,27). In contrast,
tumors of the hemopoietic system appear
most likely to develop expression following
exposure to chemotherapeutic agents
(20,27-29). The normal distribution ofP-
gp expression suggests that its physiological
role may be to expel naturally occurring
toxins from the cell (2). This hypothesis is
consistent with the substrate specificity of
P-gp that is highest against naturally occur-
ring chemotherapeutic agents (30).
Expression ofmembers ofthe mdrgene
family is induced in vivo following partial
hepatectomy (31-33) and during chemical
carcinogenesis (33). Hepatocytes derived
from livers undergoing regeneration fol-
lowing partial hepatectomy demonstrate an
increased resistance to hepatotoxins (34).
Hepatocytes isolated from rats previously
exposed to acetylaminofluorene (AAF) dis-
play an increased resistance to several cyto-
toxic drugs including actinomycin D (35).
Expression of the mdr gene family can be
induced in rat liver following acute expo-
sure to several xenobiotics (36,37).
Results and Discussion
We are evaluating the hypothesis that P-gp
is one ofa family ofproteins whose func-
tion is to pump xenobiotics and their
metabolites from cells. We have called this
process a phase III system, as it would form
the third major response (phase I and II
being metabolic transformations) that the
cell can make to a xenobiotic insult (Figure
1). By this hypothesis it would be reason-
able for the regulatory regions of the P-gp
genes, and other related excretory pump
genes, to have common regulatory elements
so their expression can be coordinately reg-
ulated by common protein in response to
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Figure 1. Hypothetical scheme for the coordination of
the metabolic transformation in phase and 11 with the
mdr-driven phase IlIl system in response to xenobiotic
induced toxic stress.
toxic stress. Thus, we might postulate that
the cell has a family of receptors that have
affinities for various classes of substrates
and, upon binding a particular xenobiotic,
are able to induce expression ofthose meta-
bolic and excretory genes whose proteins
are best able to alter and excrete the xeno-
biotic (Figure 1). The best clarified such
receptor that may form part of this super-
family is the arylhvdrocarbon (Ah) receptor
(38). Other possible candidates are the
recently identified peroxisome proliferator
receptor (39) and proteins that bind to the
antioxidant and electrophilic responsive
elements (40,41). The existence of differ-
ent receptors for the different classes of
xenobiotics that the cell may encounter is
in concordance with the various substrate
specificities of the cytochrome P450
isozymes. It would not be in the economic
interests of the cell to activate the whole
family of cvtochrome P450 enzymes to
metabolize a xenobiotic that was a sub-
strate for only one.
Previously we and others have demon-
strated that several xenobiotics are able to
induce the mdr gene expression (33,36,37,
42). One of the mnost potent mdr inducers
in the rat is 2-acetylaminofluorene (2-
AAF). In rat liver and isolated hepatocytes,
AAF is able to induce transcription of the
mndrl genes and thus elevate their expres-
sion measured at both the mRNA and pro-
tein levels (37). In monkeys AAF is also
able to induce mdr expression though the
effect is less and more variable than that seen
in the rat (Gant et al., unpublished data).
AAF is extensively and variably metabo-
lized in all species (43,44). For this reason,
we are conducting a study to determine if
AAF per se or a metabolite is responsible
for inducing mdr gene family transcription
and expression. Differential excretion of
AAF also occurs between species (44), so
we also have been trying to determine if
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Figure 2. (A) Effect of acetylaminofluorene and metabolites on multidrug expression in isolated primary cultured
hepatocytes. Lane: 1) dimethyl sulfoxide 0.1%/; 2) 2-AAF (20 pM); 3) 4-AAF (20 pM), 4) N-acetoxy-AAF (1 pM); 5) N-
acetoxy-AAF (5 pM); 6) 8-hydroxy-AAF (20 pM); 7) 1-hydroxy-AAF (20 pM); 8) 5-hydroxy-AAF (20 pM)( 9) 3-hydroxy-
AAF (20 pM). Induction was derived by determining the density of the multidrug band on the autorad relative to
that of the GAPDH band. Control (dimethyl sulfoxide 0.1 %) was taken as 1. Hepatocytes were incubated as previ-
ously described (37) for 40 hr with the compounds prior to the harvest of RNA. Northern analysis was performed as
previously described using a 353-base pair piece of the rat mdrlb cDNA (Probe RDR155) (45). (B) Effect of N-
hydroxy-AAF on multidrug expression in isolated primary cultured hepatocytes. Lane: 1) DMSO 0.1%; 2) N-hydroxy-
AAF 0.5 pM, 3) N-hydroxy-AAF 1.0 pM. Methodology was the same as that described for A.
differences in the route ofexcretion ofAAF
metabolites can explain the differential
ability of AAF to induce mdr gene expres-
sion between species (unpublished data).
All of the work described here has been
carried out in the rat primary cultured
hepatocyte model as previously described
(37). We first tested the effect of both the
ring hydroxylated and N-hydroxy metabo-
lites of AAF, to induce mdr expression
(Figures 2A and 2B). As we had antici-
pated, none of the ring hydroxylated forms
had any effect on mdr expression in this
system. In contrast, both the N-hydroxy
and its derivative the N-acetoxy-2-AAF (2-
AAAF) were able to induce mdr expression
and were 10- to 20-fold more potent as
mdr inducers than AAF. This suggested
that metabolism through hydroxylation to
either the 2-AAAF or further metabolites
was necessary for AAF to elicit increased
expression of the mdr gene. Additionally
fluorene has no ability to induce mdr gene
expression, but 2-aminofluorene which can
be acetylated to 2-AAF or activated per se
to electrophiles, is equipotent with 2-AAF
as an inducer of mdr gene expression (data
not shown).
To further establish the role N-hydroxy
metabolites in the induction of mdr gene
expression by AAF, we attempted to block
the induction of mdr gene expression by
AAF using U-naphthoflavone (o-NF). oc-
NF is an inhibitor of the cvtochrome
P4501A isoforms that are mainly responsi-
ble for the catalysis of AAF N-hydroxyla-
tion. At concentrations of 1 to 5 pM,
ux-NF was able to block the ability of AAF
to induce mdr gene expression in isolated
rat hepatocyte cultures (Figure 3).
Interestingly, uX-NF was also able to reducc
the basal expression of the mdr gene in
these cells, suggesting that there may be an
endogenous inducer present that requires
metabolism also through the cytochrome
P4501A enzymes (Figure 3, lanes 3 and 4).
To evaluate the role of deacetylases in the
formation of the reactive metabolites, wc
inhibited cellular deacetylases using
paraoxon at 1 and 5 pM and tested the
ability ofAAF and 2-AAAF to induce mndr
gene family expression under these circum-
stances. In microsomes, paraoxon com-
pletely inhibits deacetylase in the rat at 0.1
to 1.0 pM (46). Paraoxon was able to
inhibit the ability of 2-AAAF to induce
mdr gene expression but not that of AAF
(Figure 4). This demonistrated that the for-
mation of an ultimate electrophilic
metabolite was required for the induction
of mndrgene expression. IThc lack ofeffect of
paraoxon on the ability of AAF to induce
mdr gene expression can be explained by
consideration of the other possible routes
by which AAF can be metabolized to elec-
trophilic metabolites. Two other routes of
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Figure 3. Effect of a-naphthoflavone (a-NF) on AAF-
induced multidrug expression in primary cultured hepa-
tocytes. Lane: 1) DMSO (0.1%); 2) AAF (20 pM); 3)
ax-NF (1 pM); 4. a-NF (5 pM); 5) AAF (20 pM) + a-NF (1
pM); 6) AAF (20 pM) + a-NF (5 pM). Probing and analy-
sis were the same as that described for Figure 2A. AAF
and a-NF were added at the same time and co-incu-
bated for40 hr.
AAF metabolism to relative metabolites are
via formation of the highly reactive N-
hydroxy-sulfate and through formation of
the N-acetoxy-2-aminofluorene from the
N-hydroxy-AAF by N,O-acyltransferase.
The N,O-acyltransferase is unaffected by
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Figure 4. Effect of paraoxon on AAF and 2-AAAF
induction of multidrug expression in primary cultured
hepatocytes. Lane: 1) DMSO (0.1%); 2) AAF (10 pM); 3)
AAF (10 pM) + paraoxon (10 pM); 4) AAF (20 pM); 5)
AAF (20 pM) + paraoxon (10 pM); 6) 2-AAAF (2 pM); 7)
2-AAAF (2 pM) + paraoxon (1 pM); 8) 2-AAAF (2 pM) +
paraoxon (5 pM); 9) Paraoxon (10 pM). Analysis was
performed as described in Figure 2A with the com-
pounds being added to the cultures concurrently.
paraoxon. In rats, further metabolism of
the 2-hydroxy-AAF by N O-acyltransferase
appears to be more important as a route of
carcinogenic activation than sulfation (43).
Induction ofmdrgene family expression by
2-AAAF is inhibited by paraoxon, which
indicates that the 2-AAAF does not induce
per se or decompose to the N-acetyl elec-
trophile to form covalent adducts to pro-
teins. Rather, it undergoes deacetylation to
the N-acetoxy-2-aminofluorene and then
subsequent decomposition to the elec-
trophile.
The requirement for metabolism of
AAF to the N-hydroxy-2-AAF and the
potency of 2-AAAF as an inducer of the
mdr gene family demonstrates that genera-
tion of reactive electrophiles and subse-
quent protein covalent binding may be the
route by which AAF is able to induce mdr
expression in the rat hepatocyte. 2-AAAF
appears to require a deacetylation to N-ace-
toxy-2-aminofluorene to induce mdr
expression. After the electrophile is formed,
gene activation could occur either through
a direct interaction with DNA, on a gene
regulatory element, or via a protein interac-
tion. Our working hypothesis is that
induction of gene expression occurs
through a specific protein/electrophile
interaction. We know that elevation mdr
gene expression occurs through a transcrip-
tional mechanism in response to AAF and
other xenobiotics (37) and therefore we
postulate that this protein forming an
adduct with an AAF metabolite is then,
either alone or a heterodimer with another
protein, able to activate mdrgene transcrip-
tion. Our current work is aimed at identi-
fying these proteins and the mechanism by
which they are able to induce mdr and
other gene family expressions.
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